Latest Articles

Publication Date
EndoCyclic New Drug application approved by US FDA for endometriosis treatment - Pharmafile

EndoCyclic New Drug application approved by US FDA for endometriosis treatment Pharmafile

Published: March 25, 2026, 10:58 a.m.
FDA clears ENDO-205 Investigational New Drug application for endometriosis - Contemporary OB/GYN

FDA clears ENDO-205 Investigational New Drug application for endometriosis Contemporary OB/GYN

Published: March 23, 2026, 7:30 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - BioSpace

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis BioSpace

Published: March 23, 2026, 12:47 p.m.
EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis - PR Newswire

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal Precision Peptide Therapeutic for Endometriosis PR Newswire

Published: March 23, 2026, 11:30 a.m.
Application of high-intensity focused ultrasound in gynaecological diseases.

High-intensity focused ultrasound (HIFU), a noninvasive treatment method, has attracted increasing attention in recent years for the management of gynaecological diseases. This review summarizes current literature on the application of …

Published: March 23, 2026, midnight
Biomaterials for endometriosis treatment: Design, advances, and prospects.

Endometriosis is a chronic gynecological disease characterized by the presence of ectopic endometrium. Achieving effective therapeutic outcomes for endometriosis has always been a significant clinical hurdle because of the high …

Published: March 19, 2026, midnight
Lactoferrin as a Non-Hormonal Therapeutic Candidate for Endometriosis: Mechanisms and Future Directions.

The pathogenesis and progression of endometriosis may involve a complex combination of multiple factors, including chronic inflammation and oxidative stress. Hormonal therapy, the current standard for pharmacotherapy in endometriosis, causes …

Published: March 5, 2026, midnight
Detecting the body's reproductive hormonal brake against tissue overgrowth: Micrin/SgII-70.

A new humoral factor has been detected, within a project aiming to disclose the body's reproductive hormonal brake against tissue overgrowth, micrin ('my-crin'). Factor purification involved fractionation of ovine and …

Published: March 2, 2026, midnight
The predictive diagnostic value of combined serum detection of CXCL12, VEGF, and CA125 for endometriosis.

This study aims to explore the application value of stromal cell-derived factor (CXCL12), vascular endothelial growth factor (VEGF) and carbohydrate antigen 125 (CA125) in the diagnosis, staging, and clinical manifestations …

Published: March 1, 2026, midnight
Clinical Implications of Extracellular Vesicles in Endometriosis: A Systematic Review.

Endometriosis (EM) is a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus. Diagnosis has traditionally been challenging due to nonspecific symptoms and reliance on invasive …

Published: Feb. 6, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!